Randomized Prospective Comparison of Everolimus-Eluting vs. Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention-3-Year Clinical Outcomes of the EXCELLENT Randomized Trial -
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Kyung Woo | - |
dc.contributor.author | Rhee, Tae-Min | - |
dc.contributor.author | Kang, Hyun-Jae | - |
dc.contributor.author | Koo, Bon-Kwon | - |
dc.contributor.author | Gwon, Hyeon-Cheol | - |
dc.contributor.author | Yoon, Jung-Han | - |
dc.contributor.author | Lim, Do-Sun | - |
dc.contributor.author | Chae, In-Ho | - |
dc.contributor.author | Han, Kyoo-Rok | - |
dc.contributor.author | Ahn, Taehoon | - |
dc.contributor.author | Jeong, Myung-Ho | - |
dc.contributor.author | Jeon, Dong-Woon | - |
dc.contributor.author | Jang, Yang-Soo | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.available | 2020-02-27T10:42:17Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2018-06 | - |
dc.identifier.issn | 1346-9843 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3743 | - |
dc.description.abstract | Background: Everolimus-eluting stents (EES) have equivalent short-term angiographic and clinical outcomes to sirolimus-eluting stents (SES), but EES may be superior to SES with regard to long-term clinical safety. We report the 3-year clinical outcomes of EES and SES from the prospective EXCELLENT Randomized Trial (NCT00698607). Methods and Results: We randomly assigned 1,443 patients undergoing percutaneous coronary intervention 3: 1 to receive EES and SES, respectively. We investigated endpoints including target lesion failure (TLF) and individual clinical outcomes including stent thrombosis (ST) at 3 years. For EES and SES, the TLF rate was 4.82% and 4.12% (risk ratio [RR], 1.16, 95% CI: 0.65-2.06, P=0.62), respectively. Results were similar in other efficacy endpoints including target lesion revascularization. For safety endpoints, rate of all-cause death was significantly lower for EES (1.67%) than SES (3.57%; RR, 0.46; 95% CI: 0.23-0.94, P=0.03), while the incidence of cardiac death or myocardial infarction was numerically lower in EES. On 1-year landmark analysis, rates of all-cause death and major adverse cardiovascular events were significantly lower for EES than SES. Definite or probable ST was numerically 3-fold higher for SES (1.37%) compared with EES (0.46%). Conclusions: EES and SES had similar efficacy with regard to 3-year outcomes in the EXCELLENT trial, while delayed safety events all trended to favor EES. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | JAPANESE CIRCULATION SOC | - |
dc.relation.isPartOf | CIRCULATION JOURNAL | - |
dc.subject | NETWORK METAANALYSIS | - |
dc.subject | SUPERIORITY TRIAL | - |
dc.subject | PACLITAXEL | - |
dc.subject | THROMBOSIS | - |
dc.subject | SAFETY | - |
dc.subject | EFFICACY | - |
dc.subject | ARTERY | - |
dc.subject | RISK | - |
dc.subject | SORT | - |
dc.subject | PATHOLOGY | - |
dc.title | Randomized Prospective Comparison of Everolimus-Eluting vs. Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention-3-Year Clinical Outcomes of the EXCELLENT Randomized Trial - | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000433142200019 | - |
dc.identifier.doi | 10.1253/circj.CJ-17-0677 | - |
dc.identifier.bibliographicCitation | CIRCULATION JOURNAL, v.82, no.6, pp.1566 - + | - |
dc.identifier.scopusid | 2-s2.0-85047539710 | - |
dc.citation.endPage | + | - |
dc.citation.startPage | 1566 | - |
dc.citation.title | CIRCULATION JOURNAL | - |
dc.citation.volume | 82 | - |
dc.citation.number | 6 | - |
dc.contributor.affiliatedAuthor | Ahn, Taehoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Everolimus | - |
dc.subject.keywordAuthor | Percutaneous coronary intervention | - |
dc.subject.keywordAuthor | Sirolimus | - |
dc.subject.keywordAuthor | Stent | - |
dc.subject.keywordPlus | NETWORK METAANALYSIS | - |
dc.subject.keywordPlus | SUPERIORITY TRIAL | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordPlus | THROMBOSIS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | ARTERY | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | SORT | - |
dc.subject.keywordPlus | PATHOLOGY | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.